TFS Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

TFS Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-111,941	Closed	-$1.48M	–	971
2016 Q4	$1.48M	Buy	111,941 +42,051	+60%	+$719K	0.4%	48
2016 Q3	$1.66M	Buy	69,890 +34,646	+98%	+$931K	0.4%	65
2016 Q2	$1.02M	Buy	35,244 +16,761	+91%	+$546K	0.19%	173
2016 Q1	$592K	Buy	+18,483	New	+$650K	0.09%	400
2015 Q1	–	Sell	-103,843	Closed	-$3.29M	–	1238
2014 Q4	$3.29M	Buy	+103,843	New	+$3.04M	0.31%	77
2014 Q2	–	Sell	-46,667	Closed	-$1.23M	–	1499
2014 Q1	$1.23M	Sell	46,667 -30,785	-40%	-$769K	0.08%	378
2013 Q4	$1.95M	Sell	77,452 -335,354	-81%	-$7.48M	0.09%	321
2013 Q3	$8.45M	Sell	412,806 -148,168	-26%	-$3.06M	0.39%	28
2013 Q2	$11.2M	Buy	+560,974	New	+$9.96M	0.47%	25

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

TFS Capital's IPXL Position: Q1 2017 in Review

TFS Capital sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 111,941 shares — an estimated $1.48M sold.

TFS Capital first reported a position in IPXL in Q2 2013 and held it in 9 quarters. The position peaked at $11.2M in Q2 2013. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

TFS Capital reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 111,941 Impax Laboratories, Inc. shares in Q1 2017, an estimated $1.48M.
TFS Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 9 quarters.
TFS Capital's Impax Laboratories, Inc. position peaked at $11.2M in Q2 2013.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.